Phase II study of sunitinib as second-line treatment for advanced gastric cancer (Q33389519)

26 July 2017

Phase II study of sunitinib as second-line treatment for advanced gastric cancer (English)

1 reference

26 July 2017

Ana Ruiz-Garcia

15

0 references

Toshihiko Doi

7

object named as

Toshihiko Doi

1 reference

26 July 2017

1

Yung-Jue Bang

1 reference

26 July 2017

4

Narikazu Boku

1 reference

26 July 2017

Yoon-Koo Kang

2

1 reference

26 July 2017

Won K Kang

3

1 reference

26 July 2017

Hyun C Chung

5

1 reference

26 July 2017

Jen-Shi Chen

6

1 reference

26 July 2017

Yan Sun

8

1 reference

26 July 2017

Lin Shen

9

1 reference

26 July 2017

Shukui Qin

10

1 reference

26 July 2017

Wai-Tong Ng

11

1 reference

26 July 2017

Jennifer M Tursi

12

1 reference

26 July 2017

Maria J Lechuga

13

1 reference

26 July 2017

Dongrui Ray Lu

14

1 reference

26 July 2017

Alberto Sobrero

16

1 reference

26 July 2017

12 May 2010

1 reference

Investigational New Drugs

26 July 2017

1 reference

26 July 2017

29

1 reference

26 July 2017

1449-1458

1 reference

26 July 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-010-9438-y

26 July 2017

0 references

cites work

Hepatic metastases of gastric adenocarcinoma showing metabolic remission on FDG-PET despite an increase in size on CT.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Chemotherapy for metastatic gastric cancer: past, present, and future

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Cancer survival in Korea 1993-2002: a population-based study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma--a rationale for a molecular targeting strategy?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Chemotherapy for advanced gastric cancer: across the years for a standard of care

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Epidemiology of gastric cancer in Japan

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Review of second-line chemotherapy for advanced gastric adenocarcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Global cancer statistics, 2002

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Palliative chemotherapy for advanced gastric cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

21 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9438-Y

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9438-Y

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9438-Y

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9438-Y

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9438-Y

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9438-Y

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9438-Y

Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9438-Y

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9438-Y

Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.).

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171673

Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer

31 October 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9438-Y

Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9438-Y

A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study)

21 January 2018

1 reference

12 December 2020

Prognostic value of platelet-derived growth factor-A (PDGF-A) in gastric carcinoma

1 reference

12 December 2020

Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer

1 reference

12 December 2020

Prognostic value of vascular endothelial growth factor expression in gastric carcinoma

1 reference

12 December 2020

10.1007/S10637-010-9438-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference